Already a member? Sign in
Oxcarbazepine is used to treat certain types of seizures in people who have epilepsy. It is an anticonvulsant. It works by decreasing abnormal excitement in the brain.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Epilepsy | 180 | 53 |
|
|
|
|
|
| Treat my mood condition(s) | 65 | 21 |
|
|
|
|
|
| Pain | 29 | 9 |
|
|
|
|
|
| Bipolar Disorder | 23 | 13 |
|
|
|
|
|
| Trigeminal neuralgia (trigeminal nerve pain) | 22 | 6 |
|
|
|||
| Other | 20 | 2 |
|
|
See all 362 patients currently taking Oxcarbazepine
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Oxcarbazepine
| Dry mouth (xerostomia) | 10 | |
|---|---|---|
| Dizziness | 9 | |
| Excessive daytime sleepiness (somnolence) | 9 | |
| Lack of concentration | 7 | |
| Fatigue | 7 | |
| Sweating excessive | 7 | |
| See all 118 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Oxcarbazepine. See all 39 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Side effects too severe | 58 | ||
| Did not seem to work | 48 | ||
| Doctor's advice | 43 | ||
| Other | 24 | ||
| Course of treatment ended | 8 | ||
| Personal research | 6 | ||
| Change in health plan coverage | 4 | ||
| Expense | 2 |
Adherence
Taking treatment as prescribed
Adherence of Oxcarbazepine
Always |
116 | 81% |
|
|---|---|---|---|
Usually |
19 | 13% |
|
Sometimes |
5 | 3% |
|
Never |
4 | 3% |
|
Burden
Difficulty being on treatment
Burden of Oxcarbazepine
Very |
7 | 5% |
|
|---|---|---|---|
Somewhat |
21 | 15% |
|
A little |
20 | 14% |
|
Not at all |
96 | 67% |
|
Cost
Paid out of pocket
Cost of Oxcarbazepine
$200+ |
3 | 3% |
|
|---|---|---|---|
$100-199 |
7 | 7% |
|
$50-99 |
11 | 11% |
|
$25-49 |
11 | 11% |
|
< $25 |
65 | 67% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 12, 2012.